Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaume Capdevila

Showing results (71-80 of 192) with videos related to

Pageof 20
Sort By:
Cancer Metastasis Reviews|October 5, 2015
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentRocio Garcia-Carbonero, Roberto Garcia-Figueiras, Alberto Carmona-Bayonas, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2021
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study resultsMarianne Pavel, Jaroslaw B Ćwikła, Catherine Lombard-Bohas, et al.
Journal of Clinical Medicine|June 2, 2021
Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRTMeritxell Molla, Julen Fernandez-Plana, Santiago Albiol, et al.
European Thyroid Journal|July 10, 2023
Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practiceJaume Capdevila, Desiree' Deandreis, Cosimo Durante, et al.
Frontiers in Oncology|March 25, 2026
Case Report: Lorlatinib for the treatment of <i>ALK</i>-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitorJesús Yaringaño, Jorge Hernando, Alejandro García-Álvarez, et al.
Endocrinologia, Diabetes Y Nutricion|June 17, 2026
Primary hepatic gastrinoma as a clinical mimic: Favorable clinical outcomesDavid Sanchis-Pascual, Luis de Miguel-Rodríguez, Pilar Morillas-Amat, et al.
Cancer Treatment Reviews|October 8, 2018
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumoursJorge Barriuso, Ana Custodio, Ruth Afonso, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Therapeutic Advances in Endocrinology and Metabolism|March 1, 2019
Economics of gastroenteropancreatic neuroendocrine tumors: a systematic reviewEnrique Grande, Ángel Díaz, Carlos López, et al.
Pageof 20

Showing results (71-80 of 192) with videos related to

Sort By:
Pageof 20
Cancer Metastasis Reviews|October 5, 2015
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentRocio Garcia-Carbonero, Roberto Garcia-Figueiras, Alberto Carmona-Bayonas, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2021
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study resultsMarianne Pavel, Jaroslaw B Ćwikła, Catherine Lombard-Bohas, et al.
Journal of Clinical Medicine|June 2, 2021
Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRTMeritxell Molla, Julen Fernandez-Plana, Santiago Albiol, et al.
European Thyroid Journal|July 10, 2023
Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practiceJaume Capdevila, Desiree' Deandreis, Cosimo Durante, et al.
Frontiers in Oncology|March 25, 2026
Case Report: Lorlatinib for the treatment of <i>ALK</i>-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitorJesús Yaringaño, Jorge Hernando, Alejandro García-Álvarez, et al.
Endocrinologia, Diabetes Y Nutricion|June 17, 2026
Primary hepatic gastrinoma as a clinical mimic: Favorable clinical outcomesDavid Sanchis-Pascual, Luis de Miguel-Rodríguez, Pilar Morillas-Amat, et al.
Cancer Treatment Reviews|October 8, 2018
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumoursJorge Barriuso, Ana Custodio, Ruth Afonso, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Therapeutic Advances in Endocrinology and Metabolism|March 1, 2019
Economics of gastroenteropancreatic neuroendocrine tumors: a systematic reviewEnrique Grande, Ángel Díaz, Carlos López, et al.
Pageof 20